BI tims TOF fleX with MALDI-2 mass spectrometer

总结 细胞质谱仪设备已经创建了独特的协议，用于表征单个细胞 和细胞器，用于组织的高空间分辨率质谱成像和用于相关的 分子成像这些测量方法被NIH支持的研究人员广泛使用， 在伊利诺伊大学厄巴纳-香槟分校（UIUC）本地，在伊利诺伊州的区域合作机构， 印第安纳州和威斯康星州，以及全国。首要的需要是更换两个单独的十年之久的仪器 一个新的基质辅助激光解吸电离（MALDI）质谱仪，大大提高了 检测限、质量分辨率、离子迁移率分离、分析等方面的性能规格 速度和空间分辨率，以及其他进步。更具体地，所请求的布鲁克时间TOF fleX MALDI-2系统集成了多项设计改进，包括MALDI-2后电离、捕获 离子迁移率、并行累积串行碎裂、双源和许多其他设计改进 与其他工具相比。这些先进的功能和相关的品质因数使 适用于一系列需要单细胞和组织成像测量的NIH支持用户。主要分子 靶标包括脂质、代谢物、肽（包括内源性含D-氨基酸的肽）和 proteins.由于该仪器被认为是UIUC的战略收购，政府正在提供 机构资金，以支持第2-5年的服务合同。该工具将直接受益于三个NIH- 支持的中心和十几个额外的NIH支持的主要用户;广泛的投资组合的研究 收购布鲁克公司的timsTOF flex MALDI-2仪器，将促进许多研究项目。

Summary The Cellular Mass Spectrometry Facility has created unique protocols for the characterization of individual cells and cellular organelles, for high spatial resolution mass spectrometry imaging of tissues and for correlated molecular imaging. These measurement approaches are used by a broad range of NIH-supported researchers, locally at the University of Illinois Urbana-Champaign (UIUC), regionally at collaborating institutions in Illinois, Indiana and Wisconsin, and nationally. The overarching need is to replace two separate decade-old instruments with a new matrix assisted laser-desorption ionization (MALDI) mass spectrometer that has greatly enhanced performance specifications in terms of detection limits, mass resolution, ion mobility separations, analyses speeds, and spatial resolution, among other advancements. More specifically, the requested Bruker timsTOF fleX MALDI-2 system incorporates multiple design improvements, including MALDI-2 post-ionization, trapped ion mobility, parallel accumulation serial fragmentation, dual sources, and many other design improvements compared to alternative instruments. These advanced features and the associated figures of merit are enabling for a range of NIH-supported users requiring single cell and tissue imaging measurements. The major molecular targets include lipids, metabolites, peptides (including endogenous D-amino acid-containing peptides) and proteins. Because the instrument is considered a strategic acquisition by UIUC, the administration is supplying institutional funds to support the service contracts in years 2–5. This instrument will directly benefit three NIH- supported centers and more than a dozen additional NIH-supported major users; the research of a broad portfolio of research projects will be catalyzed with the acquisition of the Bruker timsTOF flex MALDI-2 instrument.